Duncan A. Greenhalgh

Duncan Greenhalgh is a senior partner in Goodwin's nationally recognized Life Sciences group where he counsels companies, entrepreneurs, investors, and investment banks on intellectual property matters. His practice focuses on developing and implementing complex intellectual property and market exclusivity strategies for emerging and mature life sciences companies, with a focus on maximizing exclusivity for biologic and chemical therapeutics. He also advises clients on intellectual property due diligences, freedom-to-operate and risk assessments, and intellectual property agreements, including collaboration and license agreements.

Dr. Greenhalgh has been consistently recognized as a leading life science patent attorney by numerous legal guides. Chambers USA recognized him for being “particularly adept at advising life sciences companies on IP and market strategy” and noted that he is “great at finding solutions and has good business acumen.”

Dr. Greenhalgh has been recognized by Chambers USA: America’s Leading Lawyers for Business (2009-2024), LMG Life Sciences (2012-2014, 2016-2024), Managing IP - IP Stars (2012-2025), The Best Lawyers in America (2017-2024) and Intellectual Asset Management’s Patent 1000 (2015-2024) as an industry leader for his intellectual property expertise in life sciences.

Dr. Greenhalgh has developed and implemented patent strategies for a variety of small molecule therapeutics and biologics, a number of which have gained US FDA and worldwide regulatory approval. He has significant experience maximizing patent exclusivities, and positioning patent and regulatory exclusivities for partnering and collaboration transactions, financing events such as venture financings and public offerings, and M&A activities. He has extensive experience in a variety of technologies, including protein and cell based therapeutics, gene therapies, small molecule therapeutics, vaccines, formulations, drug delivery, diagnostics, and AI-assisted drug discovery.

He specializes in developing and managing domestic and foreign patent portfolios, including developing, implementing and expediting complex prosecution strategies in the United States and abroad, FDA Orange Book submissions, patent term extensions, and has handled numerous post grant proceedings, including reissue, ex parte and inter partes reexamination, and interference proceedings at the United States Patent and Trademark Office, and foreign patent opposition proceedings. He counsels clients on preparing for ANDA and biosimilar competition.

Dr. Greenhalgh conducts intellectual property due diligence investigations in connection with various transactions, including investments in public and privately held companies, public offerings, licensing transactions, strategic alliances, and M&A activities.

Dr. Greenhalgh is a member of a number of professional organizations, including the American Intellectual Property Law Association, the American Bar Association, the Boston Bar Association and the Boston Patent Law Association.

Prior to joining Goodwin in 2005, Dr. Greenhalgh was a member of the Patent and Intellectual Property Group at Testa, Hurwitz & Thibeault LLP in Boston from 1993 until 2005.

Dr. Greenhalgh has been selected for inclusion in Chambers USA: America's Leading Lawyers for Business, 2009-2025.

Dr. Greenhalgh has been recognized as an industry leader for his intellectual property expertise in life sciences, including LMG Life Sciences (2012-2014 and 2016-2024), The Best Lawyers in America (2017-2025) and Managing IP - IP Stars (2012-2025), and Intellectual Asset Management’s Patent 1000 (2015-2025).

Dr. Greenhalgh is a frequent speaker on intellectual property matters both in industry settings and at Boston-area universities.